Rainer Henning

Vienna, 1190, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

VVX001 Induces preS-Specific Antibodies Reacting to Common HBV Genotypes in Hepatitis B Virus (HBV) Carrier Mice.

VVX001 Induces preS-Specific Antibodies Reacting to Common HBV Genotypes in Hepatitis B Virus (HBV) Carrier Mice.

Journal: Vaccines
Published: May 14, 2025

The PreS-Based Recombinant Vaccine VVX001 Induces Hepatitis B Virus Neutralizing Antibodies in a Low-Responder to HBsAg-Based HBV Vaccines.

The PreS-Based Recombinant Vaccine VVX001 Induces Hepatitis B Virus Neutralizing Antibodies in a Low-Responder to HBsAg-Based HBV Vaccines.

Journal: Vaccines
Published: July 23, 2024

Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes.

Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes.

Journal: Allergy
Published: June 15, 2021

Repurposing CPAP machines as stripped-down ventilators.

Repurposing CPAP machines as stripped-down ventilators.

Journal: Scientific reports
Published: September 21, 2020

Immunological imprint of COVID-19 on human peripheral blood leukocyte populations.

Immunological imprint of COVID-19 on human peripheral blood leukocyte populations.

Journal: Allergy
Published: September 18, 2020

Antibodies in serum of convalescent patients following mild COVID-19 do not always prevent virus-receptor binding.

Antibodies in serum of convalescent patients following mild COVID-19 do not always prevent virus-receptor binding.

Journal: Allergy
Published: July 04, 2020

Quantification, epitope mapping and genotype cross-reactivity of hepatitis B preS-specific antibodies in subjects vaccinated with different dosage regimens of BM32.

Quantification, epitope mapping and genotype cross-reactivity of hepatitis B preS-specific antibodies in subjects vaccinated with different dosage regimens of BM32.

Journal: EBioMedicine
Published: June 12, 2020

Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG4 response.

Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG4 response.

Journal: EBioMedicine
Published: September 11, 2019

Allergen immunotherapy with the hypoallergenic B-cell epitope-based vaccine BM32 modifies IL-10- and IL-5-secreting T cells.

Allergen immunotherapy with the hypoallergenic B-cell epitope-based vaccine BM32 modifies IL-10- and IL-5-secreting T cells.

Journal: Allergy
Published: July 23, 2019

Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.

Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.

Journal: The Journal of allergy and clinical immunology
Published: April 20, 2017

Epicutaneous allergen application preferentially boosts specific T cell responses in sensitized patients.

Epicutaneous allergen application preferentially boosts specific T cell responses in sensitized patients.

Journal: Scientific reports
Published: April 05, 2017

Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy.

Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy.

Journal: EBioMedicine
Published: January 09, 2017
Showing 1-12 of 17

Last Updated: 09/26/2026